Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory/relapsed AML: Case report and exploration of possible mechanisms

Venetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment. In this report, a relapsed/refractory (R/R) venetoclax resistant AML1-ETO positive AML patient showed rapid tumor regres...

Full description

Bibliographic Details
Main Authors: Man Li, Xiawan Yang, Yaonan Hong, Qi Liu, Yingying Shen, Tonglin Hu, Yiping Shen, Guoyin Kai, Dijiong Wu
Format: Article
Language:English
Published: Elsevier 2024-08-01
Series:Heliyon
Subjects:
Refractory/relapse
Acute myeloid leukemia
Venetoclax
Gilteritinib
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024118786

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024118786

Similar Items